Evidence map›Paper›PMID 31374940›Full record

ArticleNanomaterials (Basel, Switzerland)2019

Design of Engineered Cyclodextrin Derivatives for Spontaneous Coating of Highly Porous Metal-Organic Framework Nanoparticles in Aqueous Media.

Giovanna Cutrone, Xue Li, Juan M Casas-Solvas, Mario Menendez-Miranda, Jingwen Qiu, Gábor Benkovics, Doru Constantin, Milo Malanga, Borja Moreira-Alvarez, José M Costa-Fernandez and 3 more

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. One-Step Encapsulation ofACS applied materials & interfaces · 2021
    Article
  9. Article
  10. Cyclodextrin-Based Functional Glyconanomaterials.Nanomaterials (Basel, Switzerland) · 2020
    Review
  11. Cyclodextrins Modified/Coated Metal-Organic Frameworks.Materials (Basel, Switzerland) · 2020
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Giovanna CutroneDepartment of Chemistry and Physics, University of Almería, Crta. de Sacramento s/n, E-04120 Almería, Spain.
Xue LiInstitut des Sciences Moléculaires d'Orsay, UMR CNRS 8214, Université Paris-Sud, Université Paris Saclay, 91400 Orsay, France.
Juan M Casas-SolvasDepartment of Chemistry and Physics, University of Almería, Crta. de Sacramento s/n, E-04120 Almería, Spain.
Mario Menendez-MirandaInstitut des Sciences Moléculaires d'Orsay, UMR CNRS 8214, Université Paris-Sud, Université Paris Saclay, 91400 Orsay, France.
Jingwen QiuInstitut des Sciences Moléculaires d'Orsay, UMR CNRS 8214, Université Paris-Sud, Université Paris Saclay, 91400 Orsay, France.
Gábor BenkovicsCycloLab R&D Ltd., Illatos út 7, H-1097 Budapest, Hungary.
Doru ConstantinLaboratoire de Physique des Solides, UMR 8502, Université Paris-Sud, 91405 Orsay, France.
Milo MalangaCycloLab R&D Ltd., Illatos út 7, H-1097 Budapest, Hungary.
Borja Moreira-AlvarezDepartment of Physical and Analytical Chemistry, University of Oviedo, Julián Clavería 8, 33006 Oviedo, Spain.
José M Costa-FernandezDepartment of Physical and Analytical Chemistry, University of Oviedo, Julián Clavería 8, 33006 Oviedo, Spain.
Luis García-FuentesDepartment of Chemistry and Physics, University of Almería, Crta. de Sacramento s/n, E-04120 Almería, Spain.
Ruxandra GrefInstitut des Sciences Moléculaires d'Orsay, UMR CNRS 8214, Université Paris-Sud, Université Paris Saclay, 91400 Orsay, France. ruxandra.gref@u-psud.fr.
Antonio Vargas-BerenguelDepartment of Chemistry and Physics, University of Almería, Crta. de Sacramento s/n, E-04120 Almería, Spain. avargas@ual.es.

Funding

Agence Nationale de la Recherche ANR-10-LABX-0035Agence Nationale de la Recherche ANR-14-CE08-0017European Commission FP7-PEOPLE-2013-ITN (http://itn-cyclonhit.eu) project (Grant Agreement no. 608407)Ministerio de Economía y Competitividad Grant CTQ2017-90050-R
6 · The paper itself

Abstract

Nanosized metal-organic frameworks (nanoMOFs) MIL-100(Fe) are highly porous and biodegradable materials that have emerged as promising drug nanocarriers. A challenging issue concerns their surface functionalization in order to evade the immune system and to provide molecular recognition ability, so that they can be used for specific targeting. A convenient method for their coating with tetraethylene glycol, polyethylene glycol, and mannose residues is reported herein. The method consists of the organic solvent-free self-assembly on the nanoMOFs of building blocks based on β-cyclodextrin facially derivatized with the referred functional moieties, and multiple phosphate groups to anchor to the nanoparticles' surface. The coating of nanoMOFs with cyclodextrin phosphate without further functional groups led to a significant decrease of macrophage uptake, slightly improved by polyethylene glycol or mannose-containing cyclodextrin phosphate coating. More notably, nanoMOFs modified with tetraethylene glycol-containing cyclodextrin phosphate displayed the most efficient "stealth" effect. Mannose-coated nanoMOFs displayed a remarkably enhanced binding affinity towards a specific mannose receptor, such as Concanavalin A, due to the multivalent display of the monosaccharide, as well as reduced macrophage internalization. Coating with tetraethylente glycol of nanoMOFs after loading with doxorubicin is also described. Therefore, phosphorylated cyclodextrins offer a versatile platform to coat nanoMOFs in an organic solvent-free, one step manner, providing them with new biorecognition and/or "stealth" properties.

Indexed as

isothermal titration calorimetrymacrophagemannosemetal-organic frameworksMIL-100(Fe)molecular recognitionmultivalent effect“stealth” effectβ-cyclodextrin

Identifiers

PMID31374940
PMCPMC6723150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.